Adverse events in dupilumab therapy: a propensity matched retrospective cohort study

Arch Dermatol Res. 2024 Dec 7;317(1):82. doi: 10.1007/s00403-024-03621-w.

Ryan S Koch¹, Kyle C Lauck², Stanislav N Tolkachjov^{3

4

5

6}

¹ Texas A&M University College of Medicine, Dallas, TX, USA.
² Division of Dermatology, Baylor University Medical Center, Dallas, TX, USA.
³ Texas A&M University College of Medicine, Dallas, TX, USA. Stan.tolkachjov@gmail.com.
⁴ Division of Dermatology, Baylor University Medical Center, Dallas, TX, USA. Stan.tolkachjov@gmail.com.
⁵ Epiphany Dermatology, 1640 FM 544. Suite 100, Lewisville, TX, 75056, USA. Stan.tolkachjov@gmail.com.
⁶ Department of Dermatology, University of Texas at Southwestern, Dallas, TX, USA. Stan.tolkachjov@gmail.com.

No abstract available

Keywords: Adverse effects; Atopic dermatitis; Dupilumab; Dupixent.

Publication types